Genmab A (GMAB) Receivables - Net (2023 - 2025)

Genmab A's Receivables - Net history runs 3 years deep, the most recent figure standing at $1.1 billion for Q4 2025.

• Quarterly Receivables - Net rose 21.94% year-over-year to $1.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.1 billion (up 21.94% YoY) and the FY2025 annual result came in at $1.1 billion, up 21.94% from the prior year.
• Receivables - Net was $1.1 billion for Q4 2025 at Genmab A, up from $930.0 million in the prior quarter.
• Across five years, Receivables - Net topped out at $1.1 billion in Q4 2025 and bottomed at $743.0 million in Q4 2023.
• A 3-year average of $935.7 million and a median of $930.0 million in 2024 frame the typical range for Receivables - Net.
• Annual changes were most pronounced in 2024 — Receivables - Net gained 25.17% — and 2025, when it increased 21.94%.
• Genmab A's Receivables - Net stood at $743.0 million in 2023, then rose by 25.17% to $930.0 million in 2024, then grew by 21.94% to $1.1 billion in 2025.
• Business Quant data shows GMAB's Receivables - Net at $1.1 billion in Q4 2025, $930.0 million in Q4 2024, and $743.0 million in Q4 2023.